In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.

Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports identifying SARS-CoV-2 RDV resistance in patients, animal models or in vitro. Here, we selected drug-resistant viral populat...

Full description

Saved in:

Bibliographic Details
Main Authors:	Agnieszka M Szemiel, Andres Merits, Richard J Orton, Oscar A MacLean, Rute Maria Pinto, Arthur Wickenhagen, Gauthier Lieber, Matthew L Turnbull, Sainan Wang, Wilhelm Furnon, Nicolas M Suarez, Daniel Mair, Ana da Silva Filipe, Brian J Willett, Sam J Wilson, Arvind H Patel, Emma C Thomson, Massimo Palmarini, Alain Kohl, Meredith E Stewart
Format:	article
Language:	EN
Published:	Public Library of Science (PLoS) 2021
Subjects:	Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5
Online Access:	https://doaj.org/article/7d89e76f634d4950a6f0243895093b37
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.

Similar Items